$8.09
+1.49
(+22.58%)▲
20.89%
Downside
Day's Volatility :26.77%
Upside
7.44%
62.55%
Downside
52 Weeks Volatility :90.66%
Upside
75.06%
Period | Regencell Bioscience Holdings Ltd | Index (Russel 2000) |
---|---|---|
3 Months | 6.45% | 0.0% |
6 Months | 24.65% | 0.0% |
1 Year | -42.71% | 0.0% |
3 Years | -54.45% | -25.1% |
Market Capitalization | 90.3M |
Book Value | $0.63 |
Earnings Per Share (EPS) | -0.33 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -28.11% |
Return On Equity TTM | -43.18% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -4.4M |
Diluted Eps TTM | -0.33 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Sell
Neutral
Buy
Regencell Bioscience Holdings Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Regencell Bioscience Holdings Ltd | 67.49% | 24.65% | -42.71% | -54.45% | -22.95% |
Neurocrine Biosciences Inc. | 7.25% | -12.6% | 7.78% | 27.86% | 19.32% |
Haleon Plc Spon Ads | -7.69% | 16.95% | 22.24% | 31.31% | 31.31% |
Zoetis Inc. | -5.46% | 8.8% | 13.08% | -14.26% | 45.84% |
Viatris Inc. | 1.31% | 0.17% | 30.12% | -15.98% | -28.89% |
Catalent, Inc. | -2.85% | 4.24% | 78.56% | -56.93% | 16.95% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Regencell Bioscience Holdings Ltd | NA | NA | NA | 0.0 | -0.43 | -0.28 | NA | 0.63 |
Neurocrine Biosciences Inc. | 32.59 | 32.59 | 0.27 | 4.47 | 0.16 | 0.12 | NA | 26.87 |
Haleon Plc Spon Ads | 28.5 | 28.5 | 1.45 | 0.38 | 0.07 | 0.04 | 0.02 | 1.8 |
Zoetis Inc. | 35.75 | 35.75 | 2.58 | 5.82 | 0.49 | 0.14 | 0.01 | 10.94 |
Viatris Inc. | 224.4 | NA | 0.07 | 2.67 | -0.03 | 0.03 | 0.04 | 16.36 |
Catalent, Inc. | 211.02 | NA | 2.93 | 0.2 | -0.25 | 0.0 | NA | 19.91 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Regencell Bioscience Holdings Ltd | NA | $90.3M | -22.95% | NA | 0.0% |
Neurocrine Biosciences Inc. | Buy | $12.4B | 19.32% | 32.59 | 17.21% |
Haleon Plc Spon Ads | Buy | $43.9B | 31.31% | 28.5 | 9.66% |
Zoetis Inc. | Buy | $82.4B | 45.84% | 35.75 | 26.29% |
Viatris Inc. | Hold | $13.8B | -28.89% | 224.4 | -4.24% |
Catalent, Inc. | Hold | $10.6B | 16.95% | 211.02 | -23.81% |
Insights on Regencell Bioscience Holdings Ltd
Revenue is down for the last 2 quarters, -2.34B → -2.34B (in $), with an average decrease of 0.0% per quarter
Netprofit is down for the last 2 quarters, -1.03K → -2.23M (in $), with an average decrease of 216216.0% per quarter
In the last 1 year, Catalent, Inc. has given 78.6% return, outperforming this stock by 121.3%
we are an early-stage bioscience company that focuses on research, development and commercialization of tcm for the treatment of neurocognitive disorders and degeneration, specifically attention deficit hyperactivity disorder (“adhd”), autism spectrum disorder (“asd”) in infectious diseases such as covid-19. our goal is to improve the lives of adhd, asd and covid patients, their families and caregivers and become a market leader for the best tcm treatment globally.
Organization | Regencell Bioscience Holdings Ltd |
Employees | 12 |
CEO | Mr. Yat-Gai Au |
Industry | Miscellaneous |
Victoryshares International
$8.09
+22.58%
Clearbridge Focus Value Esg Etf
$8.09
+22.58%
Cabana Target Drawdwn 10 Etf
$8.09
+22.58%
Spdr Nyse Technology Etf
$8.09
+22.58%
Cp High Yield Trend Etf
$8.09
+22.58%
Gain Therapeutics Inc
$8.09
+22.58%
Spdr S&p Emerging Markets Ex-china Etf
$8.09
+22.58%
Proshares Bitcoin Strategy Etf
$8.09
+22.58%
Xtrackers Msci Kokusai Eqty
$8.09
+22.58%